Literature DB >> 9295177

Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders.

R P Iacono1, S M Kuniyoshi, J R Ahlman, G J Zimmerman, G Maeda, R D Pearlstein.   

Abstract

Postural instability and gait disorders (PIGD) are the primary causes of disability in many but not all advanced Parkinson's disease (PD) patients. We have measured the concentrations of serotonin, 5-hydroxytryptophan (5-HTP), 5-hydroxy-3-indoleacetic acid (5-HIAA), and homovanillic acid (HVA) in samples of ventricular cerebrospinal fluid from ten PD patients with severe disability from PIGD and from ten PD patients with tremor and levodopa induced dyskinesia as their predominant motor dysfunction. The two groups were prospectively matched for duration of disease and age. No significant differences between the two groups were found in the concentration (mean +/- SD in ng/ml, PIGD dominant vs. tremor-dyskinesia dominant) of 5-HIAA (106 +/- 50 vs. 99 +/- 34) or HVA (1,068 +/- 595 vs. 881 +/- 469). Serotonin concentration was significantly lower (0.7 +/- 0.5 vs. 1.5 +/- 0.9) and 5-HTP concentration was substantially higher (684 +/- 1,054 vs. 6 +/- 5) in the patient group with PIGD as their predominant symptoms. Thus, the distinguishing feature of patients with severe PIGD appears to be a derangement in indoleamine metabolism at the reaction step catalyzed by aromatic amino acid decarboxylase (AADC). These findings suggest that aggravation of PIGD in advanced Parkinson's may be related in part to impaired serotonergic transmission secondary to inhibition or down regulation of AADC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295177     DOI: 10.1007/BF01277663

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  28 in total

1.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

Authors:  G M Halliday; P C Blumbergs; R G Cotton; W W Blessing; L B Geffen
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

2.  Concentration gradients of monoamine metabolites in human cerebrospinal fluid.

Authors:  R Sjöström; J Ekstedt; E Anggård
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-07       Impact factor: 10.154

3.  A sensitive and rapid HPLC-ECD method for the simultaneous analysis of norepinephrine, dopamine, serotonin and their primary metabolites in brain tissue.

Authors:  M E Alburges; N Narang; J K Wamsley
Journal:  Biomed Chromatogr       Date:  1993 Nov-Dec       Impact factor: 1.902

4.  The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease.

Authors:  R P Iacono; F Shima; R R Lonser; S Kuniyoshi; G Maeda; S Yamada
Journal:  Neurosurgery       Date:  1995-06       Impact factor: 4.654

5.  Falls and Parkinson's disease.

Authors:  W C Koller; S Glatt; B Vetere-Overfield; R Hassanein
Journal:  Clin Neuropharmacol       Date:  1989-04       Impact factor: 1.592

6.  Aminergic systems in Alzheimer's disease and Parkinson's disease.

Authors:  R J D'Amato; R M Zweig; P J Whitehouse; G L Wenk; H S Singer; R Mayeux; D L Price; S H Snyder
Journal:  Ann Neurol       Date:  1987-08       Impact factor: 10.422

7.  An analysis of long-term L-dopa therapy in 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?

Authors:  T Indo; A Takahashi
Journal:  Jpn J Med       Date:  1986-05

8.  Parkinson's disease and dementia: clinical and neurochemical correlations.

Authors:  M M Strittmatter; H Cramer
Journal:  Neuroreport       Date:  1992-05       Impact factor: 1.837

9.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

Authors:  B Scatton; F Javoy-Agid; L Rouquier; B Dubois; Y Agid
Journal:  Brain Res       Date:  1983-09-26       Impact factor: 3.252

10.  Individual manifestations of Parkinson's disease after ten or more years of levodopa.

Authors:  H L Klawans
Journal:  Mov Disord       Date:  1986       Impact factor: 10.338

View more
  6 in total

1.  Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.

Authors:  Jian Ding; Jiejin Zhang; Xixi Wang; Li Zhang; Siming Jiang; Yongsheng Yuan; Junyi Li; Lin Zhu; Kezhong Zhang
Journal:  J Neural Transm (Vienna)       Date:  2016-11-22       Impact factor: 3.575

Review 2.  Normal and pathological gait: what we learn from Parkinson's disease.

Authors:  David Grabli; Carine Karachi; Marie-Laure Welter; Brian Lau; Etienne C Hirsch; Marie Vidailhet; Chantal François
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-06-29       Impact factor: 10.154

3.  Transcranial sonography image characteristics in different Parkinson's disease subtypes.

Authors:  Ai Yan Sheng; Ying Chun Zhang; Yu Jing Sheng; Cai Shan Wang; Ying Zhang; Hua Hu; Wei Feng Luo; CHun-Feng LIu
Journal:  Neurol Sci       Date:  2017-07-19       Impact factor: 3.307

Review 4.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

5.  Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters.

Authors:  Li-Jun Zuo; Ying-Shan Piao; Li-Xia Li; Shu-Yang Yu; Peng Guo; Yang Hu; Teng-Hong Lian; Rui-Dan Wang; Qiu-Jin Yu; Zhao Jin; Ya-Jie Wang; Xiao-Min Wang; Piu Chan; Sheng-Di Chen; Yong-Jun Wang; Wei Zhang
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

6.  The golden ratio of gait harmony: repetitive proportions of repetitive gait phases.

Authors:  Marco Iosa; Augusto Fusco; Fabio Marchetti; Giovanni Morone; Carlo Caltagirone; Stefano Paolucci; Antonella Peppe
Journal:  Biomed Res Int       Date:  2013-06-04       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.